Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 11 for:    MDMA | First posted from 07/30/2018 to 03/21/2020

Stanford Reward Circuits of the Brain Study - MDMA (RBRAIN-MDMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04060108
Recruitment Status : Not yet recruiting
First Posted : August 16, 2019
Last Update Posted : March 31, 2020
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Leanne Williams, Stanford University

Brief Summary:
This study is a biomarker study designed to characterize how MDMA impacts the reward circuits of the human brain.

Condition or disease Intervention/treatment
Healthy Drug: MDMA

Detailed Description:

The investigators will assess the effect of acute MDMA modulation on the functioning of reward-related human brain circuits. Reward-related brain circuits will be assessed using functional magnetic resonance imaging.

Participants will include volunteers who report more than two prior uses of MDMA (also known as Ecstasy), when they were 18 years or older.

The investigators will recruit individuals who have previously tried MDMA rather than those who are MDMA-naïve.

Participants will receive an oral dose of MDMA (~.75mg/kg and 1.5mg/kg) and placebo (saline) at 3 separate study sessions. Following established procedures, these three sessions will be randomized in a blinded protocol in order to limit expectancy effects.

Throughout each session, participants will be monitored. Functional imaging will commence after the drug has reached peak levels, following previously established time courses for MDMA administered orally. Participants will also be monitored after the functional imaging session. Secondary effects of MDMA on behavior and self-reported experience will be assessed.

In the assessment of the acute effects of MDMA, the investigators will take into account the cumulative effects of prior drug exposure.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Mapping the Influence of Drugs of Abuse on Risk and Reward Circuits - MDMA
Estimated Study Start Date : June 2020
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : December 2022

Group/Cohort Intervention/treatment
MDMA Within Subject Cross-over
Participants will be randomized to high-dose, low-dose, or placebo for each of the the three study sessions.
Drug: MDMA
.75mg/kg, 1.5 mg/kg, Placebo
Other Name: 3,4-Methyl enedioxy methamphetamine, ecstasy




Primary Outcome Measures :
  1. Reward circuit activation as assessed by functional magnetic resonance imaging [ Time Frame: up to 2 weeks after adminstration of MDMA or placebo ]
    During functional magnetic resonance imaging the reward circuit will be engaged by reward and related emotional tasks, and circuit activation will be quantified by blood flow in regions of interest and the extent of functional connectivity between them


Secondary Outcome Measures :
  1. Behavioral responses on the WebNeuro computerized test battery assessing cognitive capacity [ Time Frame: up to 5 hours after the adminstration of MDMA or Placebo ]
    Accuracy data are quantified as number of errors and lower values indicate better performance. The results across all the individual tests are aggregated to a singe report that details function as compared to a normative database.

  2. Self-reported responses as assessed by the 21-item Depression, Anxiety and Stress Scale (DASS) [ Time Frame: up to 5 hours after the adminstration of MDMA or Placebo ]
    Responses are quantified on a 4-point scale and summed for total DASS score and for each Depression, Anxiety and Subscale score. Higher scores indicate more severe symptoms of depression, anxiety and stress

  3. Self-reported responses as assessed by the Profile of Mood States (POMS) [ Time Frame: up to 5 hours after the adminstration of MDMA or Placebo ]
    Responses are quantified as summed scores for negative and positive mood states. Scores range from 1 (not at all) to 5 (extremely) and measures six different dimensions of mood swings over a period of time including: Tension or Anxiety, Anger or Hostility, Vigor or Activity, Fatigue or Inertia, Depression or Dejection, Confusion or Bewilderment.

  4. Level of subjectively experienced intoxication as assessed by a visual analogue intoxication scale [ Time Frame: up to 5 hours after the adminstration of MDMA or Placebo ]
    Responses will be quantified in intervals of 10 on a visual analogue scale of 1 to 100



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Healthy participants ages 18-55 years who have had at least two prior exposures to MDMA
Criteria

Inclusion Criteria:

  1. ages 18-55
  2. either gender and all ethno-racial categories
  3. able and willing to enroll and provide written informed consent
  4. able to comply with study procedures
  5. able to receive an MRI
  6. 2 or more prior uses of MDMA when aged 18 years or older (for MDMA arm)

Exclusion Criteria:

  1. Current active suicide ideation or history or suicide attempts
  2. Lifetime psychotic or bipolar disorder.
  3. BMI outside of healthy range (18-30)
  4. Inability to speak, read or understand English
  5. Plan to move out of the area during the study period (given repeated testing sessions)
  6. Pregnant or nursing females
  7. MRI contraindication
  8. Cannabis use in the past 7 days, alcohol use in the past 24 hours and/or other illicit recreational drug use in the 48 hours prior to sessions. In addition to self-report, these exclusion criteria will be assessed by a urine screen, saliva sample, or breathalyzer.
  9. Investigator discretion for clinical safety or protocol adherence (e.g., presence of metallic device or dental braces, which are contraindications for MRI).
  10. Use of MDMA in the past 7 days.
  11. Direct physical access to or routinely handling of addicting drugs in the regular course of work duties.
  12. Allergy or hypersensitivity to MDMA
  13. Current mood, anxiety, eating or psychotic disorder
  14. Current use of Psychotropic Medication
  15. Schizophrenia in a first degree relative.
  16. Concurrent use of any medication that might increase the risk of participation.
  17. Renal/hepatic impairment (assessed via laboratory tests during initial screening appointment)
  18. Hypertension (Hypertension, Stage 1 as defined by a systolic blood pressure >140 mmHg or diastolic blood pressure > 90 mmHg on two of three measurements at least 15 minutes apart at initial screening appointment; systolic blood pressure >155 mmHg or diastolic blood pressure >99 mmHg on two of three measurements at least 15 minutes apart during drug administration visits)
  19. Heart rate <50bpm or >150bpm assessed at initial screening visit (PI discretion for bradycardia)
  20. Chronic congestive heart failure, tachyarrhythmias, myocardial ischemia (assessed via EKG at initial screening appointment)
  21. EKG QTcF intervals >430msec for men and >470msec for women
  22. History of epilepsy, convulsions, seizures, loss of consciousness > 10 min assessed at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04060108


Contacts
Layout table for location contacts
Contact: Lauren M Whicker (650) 497-6480 laurenwhicker@stanford.edu
Contact: Jake Hartley (650) 723-3485 jakemh@stanford.edu

Sponsors and Collaborators
Stanford University
National Institute on Drug Abuse (NIDA)
Investigators
Layout table for investigator information
Principal Investigator: Leanne M Williams, PhD Stanford PI

Layout table for additonal information
Responsible Party: Leanne Williams, Professor of Psychiatry and Behavioral Sciences, Stanford University
ClinicalTrials.gov Identifier: NCT04060108    
Other Study ID Numbers: 52244
1P50DA042012-01A1 ( U.S. NIH Grant/Contract )
First Posted: August 16, 2019    Key Record Dates
Last Update Posted: March 31, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Methamphetamine
N-Methyl-3,4-methylenedioxyamphetamine
Central Nervous System Stimulants
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors
Hallucinogens
Psychotropic Drugs
Serotonin Agents